Notice
20 Jun 2025
pharmaceuticals, fda, regulatory review, patent extension, talvey
💊FDA's Regulatory Review Period for TALVEY Patent Extension Announced
The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for TALVEY and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.
Learn More